Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia


  • Please cite this article as follows: Liou Y-J, Chen M-L, Wang Y-C, Chen J-Y, Liao D-L, Bai Y-M, Lin C-C, Chen T-T, Mo G-H, Lai I-C. 2009. Analysis of Genetic Variations in the RGS9 Gene and Antipsychotic-Induced Tardive Dyskinesia in Schizophrenia. Am J Med Genet Part B 150B:239–242.


Some patients treated chronically with antipsychotics develop tardive dyskinesia (TD), an abnormal involuntary movement disorder. Typical antipsychotics block D2 dopamine receptors (D2DR) and produce D2DR supersensitivity. On contrary, regulators of G-protein signaling (RGS) can enhance the signal termination of G-protein-coupled D2DR. Besides, after prolonged inhibition of dopaminergic transmission, dopaminergic agonists induced severe dyskinesia only in RGS9 knock-out mice but not in normal mice. Therefore, variety in the human RGS9 gene may be related to susceptibility to TD. In this study, schizophrenic inpatients receiving long-term antipsychotic treatment were assessed using the Abnormal Involuntary Movement Scale twice over a 3-month interval. Only patients in whom abnormal involuntary movements were absent (non-TD group) and those who showed persistent TD (TD group) were enrolled. There were 407 patients in the study sample (TD = 252; non-TD = 155) and seven single nucleus polymorphisms (SNPs) in the RGS9 gene were genotyped for each subject. Genotype and allelic distributions of SNPs did not differ between the TD and non-TD groups in this study, with the exception that a weak trend of allelic association was seen with rs4790953 (P = 0.0399). In the haplotype analysis, a significant association of the AGG haplotype (rs8077696–rs8070231–rs2292593) of the RGS9 gene was found (permutation P = 0.007), and this is worthy of replication and further study. © 2008 Wiley-Liss, Inc.